4.0 Article

Surface-Area-Normalized Kt/V: A Method of Rescaling Dialysis Dose to Body Surface Area-Implications for Different-Size Patients by Gender

Journal

SEMINARS IN DIALYSIS
Volume 21, Issue 5, Pages 415-421

Publisher

WILEY
DOI: 10.1111/j.1525-139X.2008.00482.x

Keywords

-

Funding

  1. NIDDK NIH HHS [U01 DK049241-08] Funding Source: Medline

Ask authors/readers for more resources

Dialysis is measured as Kt/V, which scales the (lose (Kt) to body water content (V). Scaling dialysis dose to body surface area (S-dub) has been advocated. but the implications of such rescaling have not been examined. We developed a method of rescaling measured Kt/V to S-dub and Studied the effect of such alternative scaling oil the minimum adequacy Values that Might then be applied in male and female patients of varying body size. We examined anthropometric estimates of V and S (Watson vs. Dubois estimates) in 1765 patients enrolled in the HEMO study after excluding patients with amputations. An S-normalized target stdKt/V was defined, and an adequacy ratio (R) was computed for each patient as R = DIN where D = delivered stdKt/V (calculated using the Gotch-Leypoldt equation for stdKt/V) and N = the S-normalized minimum target value. In the HEMO data set, we determined the extent to which baseline (prerandomization) stdKt/V values would have exceeded such an S-based minimum target stdKt/V. The median V-wat/S-dub ratios were significantly higher in men (2134) than in women (18.50). The average of these (20) was used to normalize the Current suggested minimally adequate value (stdKt/V >= 2.0/week) to the S-normalized target value (stdKt/S >= 40 L/M-2), assuming that average modeled V = average anthropometric V. To achieve this S-normalized target, the required single-pool (sp) Kt/V was always hi-her in women than in men at any level of body size. For small patients (V-wat = 25L), required stdKt/V values were 2.05 and 2.21/week for men and women. respectively, corresponding to spKt/V values of 1.31 and 1.52/session. On the other hand, large (V-wat = 50L) male patients would need spKt/V values of only 1.0/session. Prerandomization baseline dialysis sessions in the HEMO Study were found to meet such a new S-based standard in almost all (766/773) men and in 885/992 women. An analysis of scaling dose to anthropometrically estimated liver size (L) showed similar gender ratios for for V-wat:L and V-wat:S-dub providing a potential physiologic explanation underpinning S-based scaling. S-based scaling of the dialysis dose Would require considerably higher doses in small patients and in women, and Would allow somewhat lower doses in larger male patients. Current dialysis practice would largely meet such an S-based adequacy standard if the dose were normalized to a V-wat:S-dub ratio of 20.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Nutrition & Dietetics

Residual Renal Phosphate Clearance in Patients Receiving Hemodialysis or Hemodiafiltration

Jorgen Hegbrant, Amparo Bernat, Domingo Del Castillo, Jose Luis Pizarro, Sonia Caparros, Mariano Gaspar, Carlos Jarava, Giovanni F. M. Strippoli, John T. Daugirdas

Summary: This study aimed to investigate the relationships between residual renal clearance and urine output in hemodialysis and hemodiafiltration patients. The results showed that the residual renal phosphate clearance was approximately 23% higher than residual renal urea clearance in these patients. Furthermore, urine volume was a moderately accurate surrogate for estimating residual renal phosphate clearance, but only when urine volume was above 300 mL/day.

JOURNAL OF RENAL NUTRITION (2023)

Article Urology & Nephrology

Comparison of modeled versus reported phosphate removal and modeled versus postdialysis serum phosphate levels in conventional hemodialysis

John T. Daugirdas

Summary: Predictions of phosphate removal using a 2-pool kinetic model were compared with measured values, and the results showed similarity between the two. This is important for conventional 4-hour dialysis treatments.

SEMINARS IN DIALYSIS (2023)

Article Urology & Nephrology

Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients

Aileen X. Wang, Sai Liu, Maria E. Montez-Rath, Glenn M. Chertow, Colin R. Lenihan

Summary: This study aims to examine the incidence, associations, and outcomes of posttransplant parathyroidectomy and calcimimetic use in a cohort of Medicare-insured US kidney transplant recipients. The study found that the rate of posttransplant parathyroidectomy remained stable over time, while the use of calcimimetic increased during the study period. Long dialysis vintage and pre-transplant calcimimetic use were strongly associated with posttransplant parathyroidectomy and calcimimetic use. Roughly 1 in 4 patients were hospitalized within 90 days of posttransplant parathyroidectomy, with hypocalcemia-related diagnoses being the most common complication. Parathyroidectomy was not associated with an increase in acute kidney injury compared to calcimimetic initiation.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Article Cardiac & Cardiovascular Systems

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure

Jean-Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al-Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Bela Merkely, John J. V. McMurray, Marc A. Pfeffer

Summary: The PRIORITIZE-HF study, which aimed to evaluate the benefits and risks of using SZC to intensify RAAS inhibitor therapy in patients with heart failure and reduced ejection fraction (HFrEF), was prematurely terminated due to challenges related to the COVID-19 pandemic. The study did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with SZC compared to placebo.

ESC HEART FAILURE (2023)

Article Urology & Nephrology

Clinically Indicated, Equitable Care for Ischemic Heart Disease in CKD: A Call to Action

Vikram Fielding-Singh, Glenn M. Chertow

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Editorial Material Urology & Nephrology

Survival Benefit with Hemodiafiltration Are We Convinced, and If So, What Might Be the Mechanism?

John T. Daugirdas, Christopher T. Chan

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Muscle Mass and Serum Creatinine Concentration by Race and Ethnicity among Hemodialysis Patients

Cynthia Delgado, Neil R. Powe, Glenn M. Chertow, Barbara Grimes, Kirsten L. Johansen

Summary: Among patients receiving dialysis, serum creatinine was higher in Black, Asian, and Hispanic patients than in non-Hispanic White patients. Differences in ICW did not explain the differences in serum creatinine concentration across race groups.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen

Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Hiddo J. L. Heerspink, Niels Jongs, Brendon L. Neuen, Patrick Schloemer, Muthiah Vaduganathan, Lesley A. Inker, Robert A. Fletcher, David C. Wheeler, George Bakris, Tom Greene, Glenn M. Chertow, Vlado Perkovic

Summary: The effects of newer kidney protective agents on smaller declines in eGFR have been assessed and found to be comparable to the effects on kidney failure or death due to kidney failure. This suggests that composite endpoints incorporating smaller declines in eGFR can reduce the required number of participants in clinical trials without compromising statistical power.

KIDNEY INTERNATIONAL (2023)

Article Urology & Nephrology

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients

Patrick S. Parfrey, Steven K. Burke, Glenn M. Chertow, Kai-Uwe Eckardt, Alan G. Jardine, Eldrin F. Lewis, Wenli Luo, Kunihiro Matsushita, Peter A. McCullough, Todd Minga, Wolfgang C. Winkelmayer

Summary: In the PRO2TECT trials, vadadustat was found to be comparable to darbepoetin alfa in terms of hematologic efficacy but not in major adverse cardiovascular events (MACE) in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Regional differences were observed in the rates of MACE, with higher rates in Europe for both vadadustat and darbepoetin alfa groups.

KIDNEY MEDICINE (2023)

Article Urology & Nephrology

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naive Patients

Wolfgang C. Winkelmayer, Susan Arnold, Steven K. Burke, Glenn M. Chertow, Kai-Uwe Eckardt, Alan G. Jardine, Eldrin F. Lewis, Wenli Luo, Kunihiro Matsushita, Peter A. McCullough, Todd Minga, Patrick S. Parfrey

Summary: The PRO2TECT trials compared the safety of vadadustat with darbepoetin alfa in patients with non-dialysis-dependent chronic kidney disease. The study found that there was no difference in major adverse cardiovascular events (MACE) among US patients, but a higher risk among patients treated with vadadustat outside the United States. Regional differences in MACE were observed, with higher rates in the non-US/non-Europe vadadustat group.

KIDNEY MEDICINE (2023)

Article Endocrinology & Metabolism

Hypocitraturia and Risk of Bone Disease in Patients With Kidney Stone Disease

Calyani Ganesan, I-Chun Thomas, Maria E. Montez-Rath, Glenn M. Chertow, John T. Leppert, Alan C. Pao

Summary: Hypocitraturia is common in patients with kidney stone disease and is also a risk factor for incident bone disease. However, after adjusting for demographic factors, comorbid conditions, and laboratory abnormalities, the association between hypocitraturia and osteoporosis or fracture is no longer statistically significant.

JBMR PLUS (2023)

Meeting Abstract Surgery

Estimating Life Years from Transplant in Older Candidates

M. Stedman, P. Ahearn, C. K. Liu, G. M. Chertow, J. C. Tan

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Surgery

Report From a Multidisciplinary Symposium on the Future of Living Kidney Donor Transplantation

Thomas G. Peters, John J. Fung, Janet Radcliffe-Richards, Sally Satel, Alvin E. Roth, Frank McCormick, Martha Gershun, Arthur J. Matas, John P. Roberts, Josh Morrison, Glenn M. Chertow, Laurie D. Lee, Philip J. Held, Akinlolu Ojo

Summary: Living donor renal transplantation is considered the best treatment for permanent loss of kidney function, but it has not grown in the United States for over 20 years. A virtual symposium was held to address this issue, emphasizing the ethical principles and limitations of altruism as the sole motivation for donation. The potential of donor incentives to save lives and save taxpayer money was examined, with survey data showing support for donor compensation. The importance of removing barriers in donor evaluation, expanding living donor chains, ensuring the safety of live kidney donation, and relieving donors of financial burden was emphasized.

PROGRESS IN TRANSPLANTATION (2023)

Letter Medicine, General & Internal

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants

Ogo Egbuna, Glenn M. Chertow

NEW ENGLAND JOURNAL OF MEDICINE (2023)

No Data Available